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120 Trans-Atlantic DebateINTRODUCTION
Endovascular aneurysm repair for ruptured abdominal aortic
aneurysm (REVAR) has proved superior to ruptured open
repair (ROR) in (most) comparative single and multicenter
studies. However, considerable controversy exists, and
skeptics continue to claim that REVAR is no better than ROR,
citing the small, randomized controlled Nottingham trial,1
and several nonrandomized trials,2e4 which found no
beneﬁt of REVAR over ROR. In addition, these skeptics are
also critical of the superior REVAR results being achieved in
some single centers (as well as in population-based studies)
as being simply down to selection bias (i.e., selecting the best
patients for REVAR) and possible high “turndown” rates (i.e.,
patients who are denied any invasive treatment).
Three multicenter European randomized controlled trials
(RCTs) comparing REVAR with ROR have recently reported
and added to the debate. One is from the Netherlands
(AJAX [Acute Endovascular Treatment to Improve Outcome
of Ruptured Aortoiliac Aneurysms] trial), another from
France (ECAR [Endovasculaire vs Chirurgie dans les Anev-
rysmes Rompus] trial), and the third is from the U.K.
(IMPROVE [Immediate Management of the Patient with
Rupture: Open Versus Endovascular repair] trial).5e7 Not
surprisingly, most observers hoped that these contempo-
rary RCTs would help resolve the REVAR versus ROR con-
troversy regarding the optimal treatment of ruptured
abdominal aortic aneurysm (rAAA).
WHAT IS THE EVIDENCE FROM THE RCTS?
In summary, all four RCTs observed no signiﬁcant difference
in short-term (30-day) mortality between REVAR and ROR.
Does this mean, therefore, that opponents of REVAR supe-
riority have been proven to be right and that this controversy
is settled? If you are a believer in RCTs, it should be. However,
a critical appraisal of all four RCTs reveals a number of
methodological issues that justify an alternative interpreta-
tion. The trial details, methodology and case selection pro-
tocols are summarized in Table 1 and in the following text.The Nottingham trial (UK)
This single-center RCT was analyzed on an intention-to-treat
(ITT) basis. The trial recruited 103 patients of whom only 32
(31%) were randomized. Reasons for not randomizing pa-
tients included that the patient was not ﬁt for ROR, the
patient died in the emergency room before randomization,
the patient was unable to give informed consent (uncon-
scious), patient’s age, refusal to undergo surgery, that there
was no team available, and that the surgeon thought ROR
to be more appropriate. In this RCT (with 69% of potential
patients being excluded), the 30-day mortality was 53% for
both REVAR and ROR.
The authors expressed disappointment with REVAR and
concluded that the bad results in the REVAR group
(compared with those reported in the literature) were areﬂection of the fact that there was no case selection in
RCTs compared with nonrandomized cohorts from earlier
studies. Ultimately, this trial was ﬂawed because of its small
size, the high proportion of exclusions and the fact that only
15 patients underwent REVAR.
The ECAR trial (France)
The preliminary results of this multicenter French RCT have
been presented at vascular meetings, but have not yet been
published. ECAR randomized only stable patients (systolic
blood pressure on arrival >80 mmHg, no vasopressive
drugs administered) with suitable EVAR morphology (prox-
imal neck length >10 mm, neck diameter <32 mm, neck
angulation <90). Only 107 patients were randomized. To
date, no signiﬁcant statistical difference in 30-day mortality
between the two groups has been observed, although
reasonably low mortality rates were reported for both
REVAR and ROR. Interestingly, among seven of the 14
recruiting centers, only about 50% of patients were eligible
for randomization (range 35e63%).
The AJAX trial (the Netherlands)
This multicenter RCT randomized 116 (out of 520 rAAA
patients [22%] in the Amsterdam region) and analyzed
outcomes on an ITT basis. AJAX found no signiﬁcant dif-
ference in the primary composite end point of death and/or
severe complications (REVAR 42%, ROR 47%) or mortality
(REVAR 21%, ROR 25%). However, meaningful interpreta-
tion of these data is difﬁcult because the proportion of
patients who were not randomized was almost 80%,
interobserver agreement on the computed tomographic
(CT) diagnosis of rupture was imperfect, and patients suit-
able (but severely unstable) for EVAR were not transferred
to centers capable of doing REVAR as well as ROR.
The authors also speculated that a high intraoperative
conversion rate to ROR (14%), mainly due to access failure
and type I endoleaks, as well as the inexperience of some of
the REVAR operators, negatively inﬂuenced the REVAR
outcomes. In addition, morbidity was signiﬁcantly lower for
REVAR (less postoperative mechanical ventilation, less
blood loss, less moderate-to-severe renal insufﬁciency).
The IMPROVE trial (UK)
This multicenter RCT was claimed by its authors to be both
“pragmatic” and to have a “real world design”. IMPROVE
randomized 623 patients with a clinical diagnosis of rAAA
(out of 1275 candidates [49%]) to either REVAR or ROR. CT
angiography (CTA) was performed after randomization (and
was optional for patients allocated to ROR). This meant that
when patients were allocated to a REVAR strategy and were
unsuitable for REVAR after CTA, they “switched” to ROR but
remained within the REVAR strategy group for ITT analyses.
There was no signiﬁcant difference in 30-day mortality
between the REVAR and ROR groups (35% vs. 37%).
Table 1. Methodology and limitations of four European randomized controlled trials.
Study Country Centers (n) Start End Randomization Patients planned (n) Patients recruited
(n)
Limitations
Suspected Deﬁnitive Total REVAR ROR
Nottingham1 UK 1 Sep 2002 NA Dec 2004 Unclear 100 32 15 17 Inclusion: high exclusion
rate (69%)
Team availability
ECAR5 France 14 Dec 2007 Dec 2010 Jan 2013 Per week, if
stable (after CTA)
160 107 56 51 Patient selection: stable
patients only
Operator experience: 15
elective EVAR
AJAX6 the Netherlands 3a Apr 2004 Oct 2007 Feb 2011 Block by computer
(after CTA)
80 (2004)
112 (2008)
116 57 59 Patient selection: only stable
patients could be referred to
three trial centers
Rupture diagnosis: moderate
interobserver agreement
(kappa ¼ .59)
Anatomic suitability: fair
interobserver agreement
(kappa ¼ .39)
Study: possibly underpowered
IMPROVE7 UK 30 Sep 2009 Mar 2013 Jul 2013 Block per telephone
(before CTA)
600 613 316 297 Team availability: 66%
of the week
Team experience: 20 EVAR,
ﬁve REVAR done
Inclusion before CTA: inclusion
of nonsuitable patients or
non-rAAA
Note. REVAR ¼ ruptured endovascular aneurysm repair; ROR ¼ ruptured open repair; NA ¼ not applicable; CTA ¼ computed tomographic angiography; EVAR ¼ endovascular aneurysm
repair; rAAA ¼ ruptured abdominal aortic aneurysm.
a Of the 10 centers involved in AJAX, only three centers (the “trial centers”) offered both REVAR and ROR.
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122 Trans-Atlantic DebateHowever, women allocated to REVAR had a signiﬁcantly
lower 30-day mortality than women in the ROR group (37%
vs. 57%; men: 35% vs. 32%). In addition, the average length
of stay in critical care (as well as in hospital) was signiﬁ-
cantly shorter for patients who underwent REVAR, and they
were discharged more often to home than those in the ROR
group (94% vs. 77%). The authors concluded that in the
largest pragmatic randomized trial, 30-day mortality and
costs were similar for the REVAR and ROR groups.CLOSE INSPECTION OF THESE RCTS SUGGESTS THAT THEY
MAY BE FLAWED AND NOT CONCLUSIVE REGARDING THE
REVAR VERSUS ROR CONTROVERSY
RCTs are thought to be the most rigorous method for deter-
mining whether a causeeeffect relationship exists between
treatment and outcome, and for assessing the (cost) effec-
tiveness of a treatment.8 However, RCTs can have ﬂaws and
imperfections that may render them invalid. One such ﬂaw is
randomization. All or most of the patients with a given con-
dition must be randomized. Exclusion of many (or most) pa-
tients can invalidate an otherwise good trial, and high
exclusion rates (51e78%) were evident in all four European
RCTs (Table 1). In addition, treatment allocation after CTA in
the IMPROVE trial led to the paradoxical situation where pa-
tients who were randomized to REVAR (but who were found
to be unsuitable following CTA) or who were found to have
diagnoses other than rAAA had to remain within the REVAR
limb of the trial (ITT analysis), despite receiving ROR or other
treatments. The 30-day mortality rates for the latter two co-
horts of patient groups were much higher than the 25%
observed following for REVAR (ROR 38% vs. other 33%). The
authors of IMPROVE claim that this trial represented a “real-
world setting”. We would strongly challenge this statement.
Optimal treatment dictates that management can only be
determined once a correct diagnosis has been made. Almost
half the patients in the EVAR limbwere deemed unsuitable for
REVAR and were then subjected to ROR. How can this be a fair
evaluation of REVAR? Interestingly, a per protocol analysis
shows a different picture, with a 32% 30-day mortality for
REVAR compared with 41% for ROR. Moreover, if those pa-
tients who did not undergo invasive treatment were excluded
from analysis, the 30-day mortality rate was 26% (REVAR)
versus 37% for ROR. The ECAR and AJAX trials performed CTA
before randomization, thereby allowing better randomization.
However, these two trials excluded from randomization sub-
groups of rAAA patients who were hemodynamically unstable
and technically difﬁcult or high-risk. Accordingly, these trials
did not allow a demonstration of the advantages of REVAR in
the higher-risk patients who would be expected to beneﬁt
most from the less invasive procedure.
Furthermore, in studies dealing with rapidly advancing
medical technology, outdated devices/techniques may
quickly render the results of a RCT invalid. The three most
recent European RCTs all encountered problems with delays
in recruitment, and some took over 10 years to complete.
None used any of the adjunctive technologies that have
emerged over the last few years and which constitute animportant part of the armamentarium in highly specialized
centers that are otherwise accused of being biased.9,10
Several large RCTs in the management of carotid disease
have now been challenged and new RCTs demanded as
novel therapeutic options (conservative and endovascular)
have emerged after the completion of the trials.11 In
addition, soft criteria such as “feasibility” or “inoperability”
are difﬁcult to standardize and interpret, and even hard
criteria like rupture have been shown to be subject to
important interobserver variability.
Although the feasibility of REVAR has been claimed to be
only about 40e60%,1,5e7,12e15 we have recently shown that
by employing adjunctive procedures (e.g., parallel grafts,
coiling, onyx, etc.) nearly 100% of rAAAs can be treated by
REVAR. If the recently published European RCTs had been
using even some of these adjuncts and strategies, the REVAR
results would undoubtedly have been better. In addition,
denial of invasive treatment and “conservative”or “palliative”
treatment (i.e., minimal therapy whilst awaiting death) would
also have been much less than was observed in the RCTs. In
this regard, nontreatment rates of up to 60% have been
published.16e18 In the IMROVE trial, 57% of those patients
who were not randomized (57%) did not undergo any form of
repair,7 a fact that undermines the validity of a trial when
judging the effect of a treatment like REVAR. Lastly, team
availability and experience has been an issue in all of the RCTs.
We strongly question the evaluation of a treatment modality
if the “availability of expertise” is missing, either because of
specialist availability (IMPROVE: 66% of the week) or a lack of
experience (see the prerequisites in Table 1).19,20THERE IS EVIDENCE OUTSIDE RCTS TO SUPPORT THE
SUPERIORITY OF REVAR
The authors of IMPROVE concluded that a disparity remains
between evidence derived from well-equipped, highly
specialized single centers, systematic reviews, and national
datasets. Does this mean that the latter are of no value,
wrong, or even useless? In an important article by Benson
and Hartz, the results of observational studies were
compared with those of RCTs.21 In 17 of 19 miscellaneous
treatments analyzed, the estimates of the treatment effects
from observational studies and RCTs were similar. In only
two of the 19 analyses did the combined magnitude of the
effect in observational studies lie outside the 95% conﬁ-
dence interval for the combined magnitude in the RCTs. It
was concluded that little evidence was found that estimates
of treatment effects in observational studies reported after
1984 are either consistently larger than or qualitatively
different from those obtained in RCTs. In a more recent
study, Shikata et al. compared the results of RCTs with
observational studies in a meta-analysis of gastrointestinal
surgical topics.22 They found that a quarter of observational
studies gave different results than randomized trials. How-
ever, the authors stated that observational studies offer
several distinct advantages over RCTs, including lower cost,
greater timeliness, and a broader range of patients,
and that these beneﬁts remain worthy of attention in
Table 2. Characteristics of studies evaluating the outcome after endovascular and open repair of a ruptured abdominal aortic aneurysm (rAAA).
Author(s)
(year of publication)
Study/
registry
Study
design
Period rAAA
total (n)
rAAA
randomized
(n)
REVAR ROR REVAR, %
(range)
30-d mortality, %
(range)
REVAR ROR Overall
Hinchliffe et al. (2006)1 Nottingham RCT 2002e04 103 32 15 17 47 53 53 53
Desgranges et al. (2010)5 ECAR RCT 2007e13 d 107 56 51 d d d d
Reimerink et al. (2013)6 AJAX RCT 2004e11 520 116 57 59 49 21 25 d
IMPROVE Trial
investigators
et al. (2014)7
IMPROVE RCT 2009e13 1,275 613 316 297 52 35 37 d
Bown et al. (2002)23 SR, MA 1955e98 10,809 0 10,809 0 d 48 48
Visser et al. (2007)24 SR, MA 1994e2006 478 148 330 31 22 38 41
Harkin et al. (2007)25 SR, MA 1999e2006 d 876 17 (34e100) 18a 34 21
Mastracci et al. (2008)26 SR, MA 1994e2006 3,213 436 0 100 21 d 21
Sadat et al. (2008)27 SR, MA 1994e2007 7,040 730 6,310 10 27a 31 29
Rayt et al. (2008)28 SR, MA 1950e2007 982 982 0 100 24 d 24
Takagi et al. (2011)29 SR, MA 1995e2006 d 42,888 d d NAb d d
Reimerink et al. (2013)30 SR, MA 1977e2012 14,670 d d d d 80 (74e86)
van Beek et al. (2014)31 SR, MA 1990e2012 72,614 d d d 29 40 34
McPhee et al. (2008)32 NIS Registry 2001e06 27,750 3,192 24,559 12 32a 41 36
Lesperance
et al. (2008)33
NIS Registry 2001e04 28,123 2,390 25,733 (6e11) 31a 42 (29e43)
Giles et al. (2009)34 NIS Registry 2000e05 d 2,323 26,106 8 33a 41 41
Davenport
et al. (2010)35
NSQIP Registry 2005e07 427 99 328 23 22a 37 d
Edwards et al. (2014)36 Medicare Registry 2001e08 10,998 1,126 9,872 (6e31) 34a 48 d
Veith et al. (2009)37 MC 2002e06 1,443 680 763 47 20a 36 28
Mayer et al. (2012)9 MC 1998e2011 473 198c 163c 57 16a 37 33
Note. Values are numbers unless stated otherwise. REVAR ¼ ruptured endovascular aneurysm repair; ROR ¼ ruptured open repair; NIS ¼ nationwide inpatient sample; NSQIP ¼ National
Surgical Quality Improvement Project; RCT, randomized controlled trial; SR ¼ systematic review; MA ¼ meta-analysis; MC ¼ multicenter study; NA ¼ not applicable.
a Statistically signiﬁcant difference.
b Statistically signiﬁcant difference, but no numbers given, just statement in text.
c 1998e2009 (period when EVAR and ROR were done, before “EVAR-only” approach).
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124 Trans-Atlantic Debate“real-world” clinical settings, particularly where random
allocation is not easily accepted by either clinicians or pa-
tients. Systematic reviews and meta-analyses of non-
randomized controlled trials, provided they are carried out
properly, are important tools for consolidating data from
high-quality, observational studies. Table 2 provides an
overview of the most important studies and their
outcomes.
SYSTEMATIC REVIEWS AND META-ANALYSES
In a 2002 meta-analysis of outcomes over ﬁve decades,
Bown et al. showed that the mortality rates following ROR
had not improved, despite progress in anesthesiology and
intensive care practice.23 Various systematic reviews and
meta-analysis have been published since then, covering
REVAR, ROR, or both (Table 2).23e31 In 2014, van Beek et al.
published the most comprehensive meta-analysis (involving
>70,000 patients after screening almost 6,000 references)
and ﬁnally included three RCTs, eight administrative regis-
tries, and 21 observational studies with >50 patients.31 In
summary, while it is accepted that some groups only used
REVAR in “favorable” rAAA patients, in not one of the nine
published systematic reviews was EVAR inferior to ROR.
There was a tendency towards superiority favoring REVAR
in all, while three showed REVAR to be superior. The au-
thors concluded that EVAR was not inferior to ROR, that
speciﬁc patient subgroups should be carefully studied (e.g.,
women, those with hostile anatomy), and that some of the
adjunctive technologies adopted within our own “EVAR-
only” approach would be promising.9
REGISTRIES
Administrative registries are often viewed with considerable
suspicion. However, they are probably best at representing
the “real-world” scenario, rather than a RCT like IMPROVE.
In all ﬁve registries analyzed and published, REVAR out-
performed ROR.32e36 Interestingly, results clearly show a
learning curve, with outcomes getting better in the later
years of analysis, suggesting that REVAR has even greater
potential than has been demonstrated so far.
MULTICENTER (OBSERVATIONAL) STUDIES
Two multicenter studies of particular interest are included
in Table 2.9,37 In the collected World and single center
experience with endovascular treatment of RAAA, thirteen
out of 49 centers adhered to an “EVAR-whenever-possible
protocol” and treated 1,443 patients (REVAR, n ¼ 680; ROR,
n ¼ 763). In this study, REVAR proved to be signiﬁcantly
better than ROR (30-day mortality 19.7% vs. 36.3%). The
second study, published by Mayer et al. in 2012, was the
ﬁrst (two-center) study to show that all patients with rAAA
can be safely treated by EVAR with low mortality and
turndown rates (4%) for infra- and juxtarenal rAAA, pro-
vided there is an “EVAR-only approach” protocol and
certain adjunctive procedures, as well as available materials
(see below).9DELIVERING A REVAR-ONLY STRATEGY
The Zurich group has published numerous scientiﬁc and
technological papers on the performance of REVAR since
1998, with excellent outcomes and low turndown
rates.9,19,20,37e51 From the beginning, a detailed protocol
was established, which has been reﬁned over the years. This
so-called “Zurich algorithm” focuses attention on ﬁve key
points: hemodynamics, imaging, procedure, abdominal
compartment syndrome (ACS), and teamwork.20,42,52
Hemodynamics
Hypotensive hemostasis, balloon control when necessary,
and local anesthesia have been key factors in inﬂuencing
hemodynamics within our ﬁrst protocol and the subject of
many publications.19,20,38,53,54 Interestingly, most of these
factors are now being recognized by other authors more
than a decade later. We are particularly supportive of the
importance of performing REVAR under local anesthesia
(currently used in 80% of our patients) and IMPROVE also
reported lower mortality rates where local anesthesia was
used.55 However, most patients being randomized within
the European RCTs underwent surgery under general
anesthesia, leading us to question whether those RCTs
remain valid or conclusive.
Imaging
Preoperative imaging, preferably thoracoabdominal CTA,
should always be done in patients with rAAA, especially
when under consideration for REVAR or other adjunctive
procedures.9,19,20 The patient should undergo a quick clin-
ical review and insertion of large bore peripheral lines
before quickly undergoing a CTA, which is evaluated
simultaneously by the radiologist and the vascular surgeon
while the patient gets further preparation.
Procedures
We strongly advise performing REVAR in a “daily business”
manner and atmosphere.19,20 If the team is used to
implanting bifurcated stent grafts, these tactics should not
change to aorto-mono-iliac devices and vice versa. In the
future, simulation training will also assume an important
role for improving technical skills and outcomes after
REVAR.56
ACS
ACS is a major killer after successful REVAR or ROR, and is
still frequently underdiagnosed.42,45,47 Over the last 15
years, the rate of ACS in our REVAR population remains
constantly between 20% and 25% (a prevalence supported
by other groups). Left untreated, the majority of these pa-
tients will die. Surprisingly, ACS did not seem to play a
major role in the new European RCTs, where the ACS rate
was either <10% or not mentioned. We question whether
underdiagnosis and nontreatment of ACS could have
negatively inﬂuenced the results of the latest RCTs. In any
European Journal of Vascular and Endovascular Surgery Volume 49 Issue 2 p. 116e128 February/2015 125case, all staff dealing with patients with rAAA should be
aware of the condition and know the new deﬁnitions and
recommendations of the World Society of the Abdominal
Compartment Syndrome.45,57Teamwork
Ideally, REVAR is carried out by an interdisciplinary team of
vascular surgeons, radiologists, anesthetists, and specialized
scrub nurses.19 A standardized patient pathway for RAAA
management and a reliable/experienced multidisciplinary
team are the keys to improving patient outcomes. REVAR
team training using high-ﬁdelity simulation may be helpful
in allowing less experienced colleagues to learn, practice,
rehearse, improve, and maintain team-based knowledge,
technical and human factor skills, and team attitudes in
order to manage REVAR successfully.56CONCLUSION
To us, REVAR is clearly the best treatment option for pa-
tients with a rAAA, provided the skills and materials to do it
are available. RCTs comparing REVAR and ROR are difﬁcult
to do, and those that have been published are misleading. It
is our opinion that resources would be better directed to-
wards developing endovascular skills and team training,
rather than planning for further RCTs.
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Vascular Research Group, Division of Cardiovascular Sciences, Clinical Sciences Building, Leicester Royal Inﬁrmary, Leicester LE2 7LX, UKIn this era of evidence-based medicine where randomized
controlled trials (RCTs) are king, we are constantly in search
of level I evidence to guide us. The area of ruptured
abdominal aortic aneurysms (rAAAs) is no exception, but,
unfortunately, the attainment of robust level I data has
been elusive. The difﬁculty in performing such a study is one
area in which our authors agree. The recent Dutch attempt
at an RCTdAJAXdfailed to show a difference in mortality
between open repair (OR) and endovascular aneurysm
repair (EVAR) groups.1 However, before rushing to use this
information to disparage EVAR for rAAAs, we need to
remember that these ﬁndings were limited to the small
subgroup of 20% of patients with rAAA who were hemo-
dynamically stable and anatomically suitable for EVAR as
determined by a preoperative computed tomography (CT)
scan. Given these inclusion criteria, it is little wonder that
no difference was observed.
The more recent IMPROVE trial was of a much different
design.2 Rather than comparing EVAR and OR in a subset of
patients with rAAA, this pragmatic trial compared an EVAR
approach (CT scan and EVAR if anatomically suitable) with
an OR approach (OR with or without CT scan) in all patients
with a clinical diagnosis of a rAAA. Approximately half of
patients with rAAA presenting to study sites were ran-
domized, with a common reason for noninclusion being the
unavailability of an EVAR team. Although the study in-
vestigators noted a trend towards improved results with
EVAR in women and with the use of local anesthesia, the30-day mortality rates were similar between these two
approaches by intention-to-treat analysis.
In the absence of convincing RCTs, proponents of EVAR
for rAAA have relied on single- and multicentered experi-
ences comparing OR and EVAR. As outlined in the debate,
EVAR opponents point to the inherent biases in these re-
ports and the selective reporting of results. Information
regarding the choice between OR and EVAR in these studies
is often missing or variable. An exception is the only report
of complete adoption of EVAR for all rAAA repairs, resulting
in a signiﬁcant reduction in perioperative mortality
compared with the previous “EVAR-when-possible” era.3
Of course, all of these reports, RCTs or otherwise, offer
limited information regarding the entire rAAA cohort of
patients as they include only those who undergo an
attempted repair. This is not an unimportant issue as a
recent population-based study reported that 20% and 41%
of patients with rAAA did not receive any repair in the USA
and England, respectively.4 Lower postintervention mortal-
ity was associated with larger hospital case loads, admission
on weekdays, and increased use of EVAR.
Our authors would surely agree that no repair is a poor
choice in the majority of patients compared with any type of
intervention, whether it be OR or EVAR. It is in these patients
who are “turned down”where the greatest potential beneﬁt
exists, some of whom are not transferredwhen OR is the only
option and they are deemed too high risk. The wider adop-
tion of EVAR for rAAA has the potential to create further high-
volume centers with consistently available EVAR and open
